ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not Yet Demonstrate That Long-Term Benefits of Desensitization Outweigh Short-Term Risks
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
